REGINfo: MSI - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

INDEX SEARCH RESULT

2020.07.14 | 13:00 | Permanent Information Releases / General Company News

CLARIANT

puce Clariant receives fine following a European competition law investigation - HTML (w)

2020.07.14 | 11:50 | Permanent Information Releases / General Company News

ALCON

puce Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength - HTML (w)

2020.07.14 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce ENSPRYNG® (Satralizumab) von Roche in der Schweiz zur Behandlung der Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) zugelassen - HTML (w)

2020.07.14 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers - HTML (w)

2020.07.14 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce ENSPRYNG® (Satralizumab) de Roche homologué en Suisse pour le traitement des Troubles du Spectre de la Neuromyélite Optique (Neuromyelitis Optica Spectrum Disorder, NMOSD) - HTML (w)

2020.07.13 | 07:03 | Permanent Information Releases / General Company News

ROCHE

puce New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A - HTML (w)

2020.07.13 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer - HTML (w)

2020.07.07 | 07:15 | Permanent Information Releases / General Company News

NOVARTIS

puce Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU - HTML (w)

2020.07.02 | 00:41 | Permanent Information Releases / General Company News

NOVARTIS

puce Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies - HTML (w)

2020.07.01 | 18:13 | Permanent Information Releases / General Company News

NOVARTIS

puce Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case - HTML (w)

2020.07.01 | 07:00 | Permanent Information Releases / General Company News

CLARIANT

puce Clariant completes the sale of its Masterbatches business to PolyOne for approx. USD 1.6 billion - HTML (w)

2020.06.29 | 18:45 | Permanent Information Releases / General Company News

ROCHE

puce FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer - HTML (w)

2020.06.29 | 15:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A - HTML (w)

2020.06.29 | 14:30 | Annual General Meeting / Reports

CLARIANT

puce Clariant’s shareholders approve all agenda items - HTML (w)

2020.06.29 | 11:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche’s ENSPRYNG®? (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000